Role of biOsimilaRs in Therapeutic Management of Anemia Following Chemotherapy in HEmatology and Oncology; A Prospective, Observational, Non-interventional Study (ORHEO)

NCT02140736 COMPLETED

The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma.

Details

Lead sponsor	Hospira, now a wholly owned subsidiary of Pfizer
Status	COMPLETED
Enrolment	2333
Start date	2009-09
Completion	2011-08-01

Conditions

• Chemotherapy-induced Symptomatic Anemia
• Solid Tumors
• Malignant Hemopathies
• Lymphomas
• Myelomas

Interventions

• Epoetin biosimilar

Primary outcomes

• Change and corrected Hemoglobin levels — 6 months
  Participants who have hemoglobin values between 11 and 12 g/dl after 6 months of treatment.

Countries

France